Pharmaceutical Industry Reports postpartum depression drug market | Page 2

REPORT DESCRIPTION
Postpartum Depression Drug Market – Overview
Increasing research activities for treatment of PPD is expected to propel growth of the postpartum depression drug
market during the forecast period. For instance, Sage Therapeutics is undergoing phase 3 clinical study for the
drug —Brexanolone, which might be useful in the treatment of PPD. The study started in May 2018 and is
estimated to be completed in September 2020.
Furthermore, Marinus Pharmaceuticals, is undergoing clinical phase 2 study for the drug Ganaxolone in the
treatment of PPD and other mood associated disorders. The clinical study started in June 2017 and is expected to
be completed in June 2019.
Postpartum depression (PPD), also known as postnatal depression, is a type of mood disorder that results post
pregnancy. Signs of depression include, insomnia, fatigue and sadness, loss of appetite, mood swings, anxiety, and
anger. Hormonal changes such as elevated prolactin levels, depleted oxytocin and thyroid hormone levels can be a
cause of PPD in females.